source
- Grail’s Galleri blood test sees 33% stock jump as FDA hints at favorable advisory panel outlookShares of Grail rose sharply on Monday after the FDA released documents ahead of an advisory committee meeting, suggesting a positive view of the company’s multi‑cancer blood test, Galleri. The up…
- Boehringer Ingelheim partners with Envisagenics on $1 billion AI-driven oncology collaborationBoehringer Ingelheim and AI drug discovery firm Envisagenics have signed a potential $1 billion multi‑year agreement to validate tumor‑specific targets. The deal will see Boehringer use Envisagenic…